Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient "Edoxaban Tosylate" has successfully passed review by the Center for Drug Evaluation (CDE). Edoxaban Tosylate is an oral anticoagulant medication primarily used for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for treating or preventing deep vein thrombosis and pulmonary embolism.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.